title: Priming in vitro maturation cycles with gonadotropins: salvage treatment for nonresponding patients.
abstract: OBJECTIVE
  To compare the treatment outcomes in in vitro maturation (IVM) cycles primed with human menopausal gonadotropin with those for pure IVM cycles in patients with polycystic ovary syndrome.
  
  
  METHODS
  Prospective observational.
  
  
  METHODS
  University-based tertiary medical center.
  
  
  METHODS
  Patients undergoing IVM cycles (primed IVM, 47; pure IVM, 118).
  
  
  METHODS
  IVM treatment with and without human menopausal gonadotropin stimulation.
  
  
  METHODS
  Pregnancy rates.
  
  
  RESULTS
  The clinical pregnancy rate demonstrated a tendency toward improvement in the primed IVM group (53.1% vs. 43.6%, 20.1% vs. 14.0% and 40.4% vs. 30.8%, [corrected] respectively) with better implantation and delivery rates (20.1% versus 14.4%; 95% confidence intervals 1.0-3.06 and 40.4% versus 24.6%; 95% confidence intervals 0.1-0.8, respectively). We found no significant difference in pure IVM compared with primed IVM in the number of eggs collected, size of leading follicle, fertility rate, cleavage rate, and the number of embryos transferred. Total mature eggs and maturation rate were significantly higher in the group of pure IVM (11 ± 2.1 versus 8.7 ± 0.5 and 68.5% ± 17.5% versus 60.9% ± 0.4%, respectively). Importantly, the endometrial thickness was significantly improved in primed IVM cycles (7.9 ± 1.9 mm versus 7.1 ± 0.8 mm), possibly leading to better implantation and pregnancy rates.
  
  
  CONCLUSIONS
  Patients who fail to demonstrate endometrial or follicular growth during IVM cycles may benefit from gonadotropin priming during the same cycle.
authors: Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada. 100paz@walla.co.il
authors: Einat
authors: E
authors: Shalom-Paz
authors: Benny
authors: B
authors: Almog
authors: Amir
authors: A
authors: Wiser
authors: Ishai
authors: I
authors: Levin
authors: Shauna
authors: S
authors: Reinblatt
authors: Mousmi
authors: M
authors: Das
authors: Weon-Young
authors: WY
authors: Son
authors: Holzer
authors: H
authors: Hananel
mesh_terms: D000046:Academic Medical Centers; D000328:Adult; D002478:Cells, Cultured; D010064:Embryo Implantation; D004624:Embryo Transfer; D005260:Female; D005298:Fertility; D005300:Fertility Agents, Female / Q000627:therapeutic use*; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D006801:Humans; D007247:Infertility, Female / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D007986:Luteinizing Hormone / Q000627:therapeutic use*; D054315:Oocyte Retrieval; D009865:Oocytes / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000503:physiopathology; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D011792:Quebec; D016896:Treatment Outcome
chemical_list: D005300:Fertility Agents, Female; D043373:Follicle Stimulating Hormone, Human; D007986:Luteinizing Hormone